LISATA THERAPEUTICS, INC. — Director's Dealing 2015

Dec 23, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2015-12-22

Reporting Person: Preti Robert A (Director, See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-12-22	Stock Option (right to purchase)	$1.12	A	200000	Acquired	2025-12-21	Common Stock, par value $0.001 per share (200000)	Direct

Footnotes

F1: On December 22, 2015 (the "Grant Date"), the Reporting Person was granted an option under the Company's 2015 Equity Compensation Plan (the "Plan") to purchase shares of the Issuer's common stock, subject to all of the terms and conditions of the Plan. This option vests as follows: 50,000 shares on the Grant Date, with the remaining 150,000 shares vesting in even increments of 12,500 shares quarterly over a period of 36 months.